{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:27:23Z","timestamp":1765603643359,"version":"3.48.0"},"reference-count":14,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2020,6,29]]},"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:p>The determination of molecular aberrations within tumours is important for diagnostic, prognostic and predictive purposes. Pathologists play a critical role in the workflow of molecular diagnostics, by assuring accurate pathological diagnosis, requesting appropriate molecular testing, selecting the adequate tissue section for molecular analysis, enriching tumour cell content by manual macrodissection and estimating the tumour cellularity. Particularly, the assessment of the malignant cell fraction within a tumour section is a key determinant for an appropriate interpretation of the molecular findings. Several factors may impact the estimation of tumour cellularity and constitute a potential pitfall for the final interpretation of the molecular analysis. Evidence suggests that the reliability of morphological control could be improved by training. The scope of this commentary is to provide the training morpho-molecular pathologists with the practical tools necessary to master microscopic morphological control for solid tumours, as well as a set of images that could serve as a training set.<\/jats:p>","DOI":"10.1136\/jclinpath-2020-206890","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T17:16:22Z","timestamp":1596734182000},"page":"331-333","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Morphological control for molecular testing: a practical approach"],"prefix":"10.1136","volume":"74","author":[{"given":"Irene","family":"Gullo","sequence":"first","affiliation":[{"name":"Department of Pathology, CHUSJ \u2013 Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o EPE, Porto, Portugal"},{"name":"Department of Pathology, FMUP \u2013 Faculty of Medicine of the University of Porto, Porto, Portugal"}]},{"given":"Ana","family":"Marques","sequence":"additional","affiliation":[{"name":"Department of Pathology, CHUSJ \u2013 Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o EPE, Porto, Portugal"},{"name":"Department of Pathology, FMUP \u2013 Faculty of Medicine of the University of Porto, Porto, Portugal"},{"name":"IPATIMUP Diagnostics, IPATIMUP \u2013 Institute of Molecular Pathology and Immunology of Porto University, Porto, Portugal"}]},{"given":"Regina","family":"Pinto","sequence":"additional","affiliation":[{"name":"IPATIMUP Diagnostics, IPATIMUP \u2013 Institute of Molecular Pathology and Immunology of Porto University, Porto, Portugal"}]},{"given":"Luis","family":"Cirnes","sequence":"additional","affiliation":[{"name":"IPATIMUP Diagnostics, IPATIMUP \u2013 Institute of Molecular Pathology and Immunology of Porto University, Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3711-8681","authenticated-orcid":false,"given":"Fernando","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Department of Pathology, FMUP \u2013 Faculty of Medicine of the University of Porto, Porto, Portugal"},{"name":"IPATIMUP Diagnostics, IPATIMUP \u2013 Institute of Molecular Pathology and Immunology of Porto University, Porto, Portugal"}]}],"member":"239","published-online":{"date-parts":[[2020,8,6]]},"reference":[{"key":"2025121221223128000_74.5.331.1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2017-0388-CP"},{"key":"2025121221223128000_74.5.331.2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.5858\/arpa.2016-0554-CP","article-title":"Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for clinical pathology, College of American pathologists, association for molecular pathology, and American Society of clinical oncology","volume":"141","author":"Sepulveda","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"2025121221223128000_74.5.331.3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00428-016-2042-6","article-title":"Adequately defining tumor cell proportion in tissue samples for molecular testing improves interobserver reproducibility of its assessment","volume":"470","author":"Lhermitte","year":"2017","journal-title":"Virchows Arch"},{"key":"2025121221223128000_74.5.331.4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/PAI.0b013e318299a1f6","article-title":"Automated objective determination of percentage of malignant nuclei for mutation testing","volume":"22","author":"Viray","year":"2014","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2025121221223128000_74.5.331.5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.5858\/arpa.2017-0269-RA","article-title":"Molecular diagnostics in pathology: time for a next-generation pathologist?","volume":"142","author":"Fassan","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"2025121221223128000_74.5.331.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2017.01.011"},{"key":"2025121221223128000_74.5.331.7","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2012-0561-CP"},{"key":"2025121221223128000_74.5.331.8","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.134"},{"key":"2025121221223128000_74.5.331.9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jmoldx.2018.03.003","article-title":"External quality assessment identifies training needs to determine the neoplastic cell content for biomarker testing","volume":"20","author":"Dufraing","year":"2018","journal-title":"J Mol Diagn"},{"key":"2025121221223128000_74.5.331.10","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0b013e3182026d72"},{"key":"2025121221223128000_74.5.331.11","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2014-202404"},{"key":"2025121221223128000_74.5.331.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2014.03.004"},{"key":"2025121221223128000_74.5.331.13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5858\/arpa.2017-0208-RA","article-title":"Cytology smears in the era of molecular biomarkers in non-small cell lung cancer: doing more with less","volume":"142","author":"Lozano","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"2025121221223128000_74.5.331.14","doi-asserted-by":"crossref","first-page":"27938","DOI":"10.18632\/oncotarget.4391","article-title":"Automated tumor analysis for molecular profiling in lung cancer","volume":"6","author":"Hamilton","year":"2015","journal-title":"Oncotarget"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2020-206890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:22:44Z","timestamp":1765603364000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2020-206890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,6]]},"references-count":14,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,4,19]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1136\/jclinpath-2020-206890"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2020-206890","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"type":"print","value":"0021-9746"},{"type":"electronic","value":"1472-4146"}],"subject":[],"published":{"date-parts":[[2020,8,6]]}}}